|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:activeIngredient
|
gptkb:dupilumab
|
|
gptkbp:age
|
adults
children (age varies by indication)
|
|
gptkbp:ATCCode
|
gptkb:L04AC13
|
|
gptkbp:brand
|
gptkb:Dupixent
|
|
gptkbp:developer
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:FDAapprovalDate
|
2017
|
|
gptkbp:form
|
pre-filled pen
pre-filled syringe
|
|
gptkbp:genericName
|
gptkb:dupilumab
|
|
gptkbp:halfLife
|
~21 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dupixent (dupilumab)
|
|
gptkbp:indication
|
gptkb:prurigo_nodularis
gptkb:atopic_dermatitis
asthma
chronic rhinosinusitis with nasal polyposis
eosinophilic esophagitis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:interleukin-13_signaling
gptkb:interleukin-4_receptor_alpha
|
|
gptkbp:mechanismOfAction
|
IL-4 receptor alpha antagonist
|
|
gptkbp:pregnancyCategory
|
N/A (consult physician)
|
|
gptkbp:prescriptionRequired
|
https://www.dupixent.com/
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
conjunctivitis
injection site reactions
eye inflammation
oral herpes
|
|
gptkbp:bfsParent
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|